The Effect Of Benazepril On The Levels Of Matrix Metallorotinese-9 And C-reactive Protein In Patients With Acute Coronary Syndrome

Background: Matrix metalloproteinases(MMPs) are a kind ofzinc-dependant endopeptidases family with the ability of degrading theextracelluler matrix, and MMP-9 is one of the important members ofthis family. Studies have reported that the MMP-9 was closely correlatedwith the unstability of atherosclerotic plaques and the development ofacute coronary syndrome (ACS). It was reported that MMP-9 can impairevascular endothelial cell function by degrading extracellular matrix andpromote the migration and hyperlasy of the intercellular smooth muscle,it also can enhance the infiltration of the inflammatory cells which maydestroy the vessel wall and plaques. Besides that, inflammation alsoparticipates in the disruption of plaques. The c-reactive protein(CRP) isthe most sensitive marker of inflammation. Examing the CRP levels inplasma may be useful for the prediction, diagnosis and prognosis for ACS.There have been a lot of studies identified that the angiotensin convertingenzyme inhibitor(ACEI) can improve the prognosis of patients with acutemyocardial infarction and those with high risk factors for cardiovasculardiseases. One of the mechanisms of action may be anti-inflammatory andplaque stabilizing.Objective: To explore the effect of Benazepril on the levels ofMMP-9 and CRP in patients with ACS. Methods: 44 patients with ACS were randomly divided intoBenazapril treatment group(n=22, patients receiving Benazapril androutine therapy) and routine therapy group(n=22, patients receivingroutine therapy without ACEI). The levels of MMP-9 and CRP weredetermined. Meanwhile, 20 healthy subjects were selected as healthycontrols.Results:①Before treatment, the levels of MMP-9 and CRP inpatients with ACS were significantly higher than in the healthy controls(both p＜0.01); but there were no statistical differences about levels ofMMP-9 and CRP between the ACEI treatment group and routine therapygroup (both p＞0.05).②After 10 days of treatment, the levels of MMP-9and CRP in ACEI treatment group and in routine therapy group weresignificantly lower than before treatment (P＜0.01 and＜0.05 repectively),while the ACEI treatment group presented more significance(bothP＜0.01).③The levels of MMP-9 had no correlation with the CRP levelswhether before or after treatment..Conclusions: The levels of MMP-9 and CRP in patients with ACSare significantly higher than in the controls. Benazepril can lower thelevels of MMP-9 and CRP. However, the MMP-9 levels have norelationship with the changes of CRP levels. ACEI may benefit forpatients with ACS by decreasing the levels of MMP-9 and playing theeffect of anti-inflammation...